✓ July 2006 – The DNA Research Center Ltd. is established by scientists from the Polish Academy of Sciences at the Poznań Science and Technology Park.

✓ July 2007 – The Non-Public Healthcare Institution Medical Genetics Laboratory of the DNA Research Center is established at Mickiewicza Street 31 in Poznań.

✓ Year 2009 – DNA Research Center Ltd. secures its first EU grants to fund projects focused on expanding and automating technological processes and implementing innovative DNA testing technology based on DNA microarray technique. Between 2009 and 2014, the company secured approximately PLN 30 million in grants and successfully completed several development projects.

✓ June 2010 – All shares of DNA Research Center Ltd. are contributed by the owners, Mr. Michał Kaszuba and Mr. Jacek Wojciechowicz, to a newly established entity: Inno-Gene S.A.

✓ October 2010 – The General Meeting of Shareholders (GMS) adopts a resolution to list Inno-Gene S.A. shares on the alternative trading system (NewConnect). New shareholders include companies from the Blumerang S.A. capital group, which acquire shares in the new issuance.

✓ February 2011 – First listing on the NewConnect market.

✓ Year 2012 – PZU Asset Management acquires a 6.6% stake in the company.

✓ June 2014 – Mr. Jacek Wojciechowicz, former Vice President, is appointed President of the Management Board.

✓ October 2018 – Inno-Gene S.A. becomes involved in creating the Genomic Map of Poland. The project’s total value was approximately PLN 105 million. To implement the project, a special purpose company, Central Europe Genomics Center Ltd., was established.

✓ September 2020 – A patent application is filed for a rapid genetic test for SARS-COV-2 diagnostics. The test, based on the RT-LAMP method, is named SARS-CoV-2 RT-LAMP Fast Detection Kit. During the COVID-19 pandemic, the company supported passenger testing at three Polish airports (Poznań-Ławica, Kraków-Balice, and Warsaw-Modlin) with this invention.

✓ September 2024 – An investment agreement is signed with Mr. Maciej Ganczarski and Hydrogenium PSA, under which Maciej Ganczarski will contribute 150,000 shares of HYDROGENIUM, representing 73% of HYDROGENIUM’s share capital and total voting rights, in exchange for 27,380,000 series H ordinary bearer shares issued by the Company.

✓ October 2024 – A resolution by the Issuer’s General Meeting of Shareholders changes the company name to HyEnergy S.A. Subsequently, an agreement with Mr. Maciej Ganczarski (“MG”) for the subscription of series H shares in Inno-Gene S.A. and the transfer of ownership of Hydrogenium PSA shares (“HYDROGENIUM”) is concluded. According to the agreement, MG subscribed for 27,380,000 series H shares in the Company, which were paid through a contribution of 150,000 shares of HYDROGENIUM, representing 73.17% of HYDROGENIUM’s share capital and voting rights. The contributed assets included 45,955 series A ordinary bearer shares and 104,045 series AZ ordinary bearer shares. The value of the contributed assets is PLN 13,690,000.00.